Dexcom, Inc. · NASDAQ:DXCM
Dexcom — JP Morgan Healthcare Conference 2018
26 slides from Dexcom's conference presentation, Jan 9, 2018
Slide 1: Dexcom Transforming Diabetes Care
Dexcom Transforming Diabetes Care January 2018 JP Morgan Healthcare Conference Exhibit 99.01
Slide 2: Safe Harbor Statement
This presentation contains forward-looking statements that are not purely historical regarding DexCom’s or its management’s intentions, beliefs, expectations and strategies for the future. All forward-looking statements and reasons why results might differ included in this presentation are made as o
Slide 3: 2017 Achievements
2017 Achievements Financial Summary Record 2017 revenue of approximately $715 million, +25% over 2016. Met 2017 patient base goal. Record Q4-17 revenue of approximately $218 million, +27% over Q4-16. Q4-17 US revenue up approximately 24% YoY. Q4-17 OUS revenue increased by more than 50% YoY. 24% >50
Slide 4: FY18 Outlook
FY18 Outlook Estimating total FY18 revenue of approximately $830 to $850 million. Sensor volumes, OUS revenue and patient base growth each to exceed revenue growth. Gross margin expected to range between 65% to 68% for 2018. Core GAAP operating expenses anticipated to increase by 10% over 2017. Excl
Slide 5: FY18 Key Strategic Objectives
FY18 Outlook Obtain approval for and launch Dexcom’s no-calibration G6 CGM platform globally. Confirm value of CGM through non-intensive T2 programs. Focus on rollout of Dexcom CGM to the Medicare population. Continue OUS expansion, including additional direct markets and new geographies (Japan, Kor
Slide 6: CGM & Diabetes Management
CGM & Diabetes Management
Slide 7: Diabetes Management Ecosystem
Diabetes Management Ecosystem Pens Disposable Pumps Durable Pumps and Supplies Insulins Other T2 Compounds Other Medications Blood Glucose Meters Continuous Glucose Monitoring Other Algorithms Outcome Measurement Decision Support & Coaching Clinicians Hospitals Education
Slide 8: Managing diabetes is a challenging balancing act
Cardiovascular disease Blindness Kidney failure Nerve degeneration Diminished cognitive function Loss of consciousness Potential death HEALTHY GLUCOSE RANGE Of the time patients are outside healthy range 1 1) Murata GH, Hoffman RM, Shah JH, Wendel CS, Duckworth WC: A probabilistic model for predicti
Slide 9: Intermittent monitoring is not enough
210 280 350 2 4 6 8 10 12 14 16 18 20 22 Glucose (mg/dl) 0 Time (hours) 24 120 SMBG* HEALTHY GLUCOSE RANGE 140 80 *Self Monitoring of Blood Glucose (SMBG) Intermittent monitoring is not enough
Slide 10: Intermittent monitoring is not enough
210 280 350 2 4 6 8 10 12 14 16 18 20 22 Glucose (mg/dl) 0 HEALTHY GLUCOSE RANGE Time (hours) 140 80 24 DANGEROUS LOW FOR 1 HOUR OVER 4 HOURS ABOVE 210 BEFORE SMBG ABOVE 140 FOR 13.5 HOURS CGM *Self Monitoring of Blood Glucose (SMBG) Intermittent monitoring is not enough
Slide 11: Only real-time CGM can alert a patient to take necessary action
210 280 350 2 4 6 8 10 12 14 16 18 20 22 Glucose (mg/dl) 0 HEALTHY GLUCOSE RANGE Time (hours) 140 80 24 DANGEROUS LOW FOR 1 HOUR OVER 4 HOURS ABOVE 210 BEFORE SMBG ABOVE 140 FOR 13.5 HOURS CGM *Self Monitoring of Blood Glucose (SMBG) Intermittent or Flash monitoring is not enough Only real-time CGM
Slide 12: This is where it starts
This is where it > STA RTS
Slide 13: Leading performance begins with accuracy
G5 Mobile (2015) Leading performance begins with accuracy G6 raises the bar 17% STS 3-Day (2006) SEVEN (2007) SEVEN Plus (2008) G4 PLATINUM (2012) G6 No Cal (Pre-Pivotal) 30% 25% 20% 15% 10% 5% 0% Accuracy (MARD) % Dexcom System MARD* by Generation 16% 13% 9% 26% * Mean Absolute Relative Difference
Slide 14: Performance that drives outcomes
Performance that drives outcomes DIaMonD results published in JAMA demonstrated a 1.0% reduction in mean A1c from baseline with CGM alone3 Baseline Week 12 Week 24 1) Diabetes 1996;45:1289-1298; Lancet. 1998; 352:837-853. 2) American Diabetes Association. Eeg-Olofsson K, et al "HbA1c reduction and r
Slide 15: Dexcom is the leader in continuous glucose measurement
Dexcom is the leader in continuous glucose measurement Industry leading performance expected to improve with G6 Continuous, real-time glucose data with alerts & alarms Completely eliminate finger sticks Patient experience: New applicator, smaller size, ease-of-use Connectivity: Share, iOS/Android, i
Slide 16: G6: Focused on the patient experience
G6: Focused on the patient experience Size Reduction No Calibration 10-Day Sensor Wear Interference Blocking Improvement in Performance & Stability App Enhancements G6 No Cal2 9.3% 91% 10.3% 89% ALL DATA Day 1 Overall G5 2/day2 MARD3 %20/204 9.0% 93% Within 20 mg/dL 10.7% 84% 1) G5 Data on file – ad
Slide 17: Interoperability: Insulin Delivery
Interoperability: Insulin Delivery Dexcom empowers user choice Smart Insulin Pens Insulin Patch Pumps Insulin Pumps
Slide 18: Interoperability: Wearables & Data Analytics
Interoperability: Wearables & Data Analytics Real-time CGM with connectivity enables convenience & tools
Slide 19: We are currently addressing a focused market
We are currently addressing a focused market 1) Chart source: As of 2017; patient populations are approximate based on internal company estimates. 1 Current CGM patients
Slide 20: But CGM will play a role for all people with diabetes
But CGM will play a role for all people with diabetes 1) Chart source: As of 2017; patient populations are approximate based on internal company estimates. 1 Current CGM patients
Slide 21: The future of CGM technology
+ Real-Time CGM Factory Calibrated 14-Day Sensor Wear Single-Use Transmitter Simple Application Significant Cost Reduction The future of CGM technology
Slide 22: Diabetes Management Program
Diabetes Management Program CGM will play a key role to help manage all patients with diabetes Assign Wearable Sensors Based on risk profile Teach Skills Customized to teach glucose control based on risk profile Compile Data Using data available from: Claims Rx/Medication Sensors Assess Disease Stat
Slide 23: CGM drives an impact in all people with diabetes
CGM drives an impact in all people with diabetes 212 mg/dL Average glucose (CGM) 150mg/dL Average glucose (CGM) 72% HIGH 28% IN RANGE 0.0% LOW Time in range 21% HIGH 79% IN RANGE 0.0% LOW Time in range IMPROVEMENT IN TIME-IN-RANGE 29% DECREASE IN AVERAGE GLUCOSE 3X First Two Weeks Last Two Weeks
Slide 24: Diabetes Management Program: key questions answered
Diabetes Management Program CGM will help answer more key questions for all patients with diabetes 180 80 You’ve had a spike the last three days at 1pm. Medication is best taken before bedtime 1Fortmann, Addie L., Linda C. Gallo, Maria Isabel Garcia, Mariam Taleb, Johanna A. Euyoque, Taylor Clark, J
Slide 25: Benefits to every healthcare constituent
Our technology that can deliver benefits to every healthcare constituent through improved outcomes and reduced costs Clinicians Patient Populations Payor Navigate day to day decisions; feedback loop for precision understanding of glucose response Navigate who needs more attention; develop hyperperso
Slide 26: CGM to empower all people with diabetes
CGM to empower all people with diabetes